TR200100622T2 - NAB1 ve NAB2'nin farmasötik kullanımları - Google Patents

NAB1 ve NAB2'nin farmasötik kullanımları

Info

Publication number
TR200100622T2
TR200100622T2 TR2001/00622T TR200100622T TR200100622T2 TR 200100622 T2 TR200100622 T2 TR 200100622T2 TR 2001/00622 T TR2001/00622 T TR 2001/00622T TR 200100622 T TR200100622 T TR 200100622T TR 200100622 T2 TR200100622 T2 TR 200100622T2
Authority
TR
Turkey
Prior art keywords
nab1
nab2
pharmaceutical uses
polypeptide
polypeptides
Prior art date
Application number
TR2001/00622T
Other languages
English (en)
Turkish (tr)
Inventor
Braddock Martin
Jeffrey Campbell Callum
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200100622T2 publication Critical patent/TR200100622T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR2001/00622T 1998-07-11 1999-07-09 NAB1 ve NAB2'nin farmasötik kullanımları TR200100622T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method

Publications (1)

Publication Number Publication Date
TR200100622T2 true TR200100622T2 (tr) 2001-10-22

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00622T TR200100622T2 (tr) 1998-07-11 1999-07-09 NAB1 ve NAB2'nin farmasötik kullanımları

Country Status (22)

Country Link
EP (1) EP1097200A1 (no)
JP (1) JP2002520020A (no)
KR (1) KR20010071832A (no)
CN (1) CN1317045A (no)
AP (1) AP2001002038A0 (no)
AU (1) AU763713B2 (no)
BR (1) BR9912018A (no)
CA (1) CA2336805A1 (no)
EA (1) EA200100028A1 (no)
EE (1) EE200100020A (no)
HR (1) HRP20010025A2 (no)
HU (1) HUP0102835A3 (no)
ID (1) ID27742A (no)
IL (1) IL140533A0 (no)
IS (1) IS5788A (no)
NO (1) NO20010166L (no)
NZ (1) NZ509174A (no)
PL (1) PL345507A1 (no)
SK (1) SK382001A3 (no)
TR (1) TR200100622T2 (no)
WO (1) WO2000003014A1 (no)
YU (1) YU1901A (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
WO2002022176A1 (en) 2000-09-15 2002-03-21 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
IL140533A0 (en) 2002-02-10
EP1097200A1 (en) 2001-05-09
SK382001A3 (en) 2001-09-11
KR20010071832A (ko) 2001-07-31
PL345507A1 (en) 2001-12-17
CA2336805A1 (en) 2000-01-20
NZ509174A (en) 2003-08-29
YU1901A (sh) 2005-06-10
AU763713B2 (en) 2003-07-31
NO20010166D0 (no) 2001-01-10
EE200100020A (et) 2002-06-17
EA200100028A1 (ru) 2001-08-27
CN1317045A (zh) 2001-10-10
HUP0102835A3 (en) 2003-09-29
NO20010166L (no) 2001-03-06
BR9912018A (pt) 2006-01-31
ID27742A (id) 2001-04-26
JP2002520020A (ja) 2002-07-09
AU4791499A (en) 2000-02-01
HRP20010025A2 (en) 2001-12-31
WO2000003014A1 (en) 2000-01-20
IS5788A (is) 2000-12-22
HUP0102835A2 (hu) 2001-11-28
AP2001002038A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ATE510558T1 (de) Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
FI955552A (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69020018D1 (de) Gentechnologische menschliche Cholinesterasen.
EP1114862A3 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
TR200100622T2 (tr) NAB1 ve NAB2'nin farmasötik kullanımları
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
BR9809712A (pt) Formas de dosagem de sertralina em solução encapsulada de gelatina
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen
TR200102265T2 (tr) Anestezi düzenlemesi.
ATE267611T1 (de) MENSCHLICHES ßMINOR VAULTß PROTEIN P193
TR199901385T2 (xx) Piperidin t�revleri.
DE69529235D1 (de) Menschliche dnase i varianten